Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

U.S. court denies Jazz Pharma bid to revive patents on narcolepsy drug

A U.S. appeals court ruled invalid patents owned by Jazz Pharmaceuticals covering the company’ narcolepsy drug Xyrem, opening the door for Amneal Pharmaceuticals to launch a generic version of the medicine.

Read More »

Harmony Biosciences Gains U.S. Rights to Pitolisant, Raises $270 Million

Startup Harmony Biosciences spun out of France-based Paragon Biosciences with $270 million in financing and the exclusive U.S. rights to narcolepsy drug pitolisant.

Read More »

82% of U.S. Adults Have Trouble Sleeping, finds Packaged Facts report

206 million American adults struggling to get a good night’s rest seek out sleep management solutions to deal with conditions such as insomnia, sleep apnea, narcolepsy, and more.

Read More »

FDA approves generic version of Jazz Pharma’s sleep disorder drug

The U.S. Food and Drug Administration approved the first generic version of Xyrem, Jazz Pharmaceuticals Plc’s drug to treat patients with narcolepsy, a kind of sleeping disorder.

Read More »

Scientists find new evidence on GSK vaccine link to narcolepsy

Scientists investigating why a GlaxoSmithKline flu vaccine triggered narcolepsy in some people say they have the first solid evidence the rare sleep disorder may be a so-called “hit-and-run” autoimmune disease. The researchers were trying to find out why, of two different flu vaccines widely deployed during the 2009/2010 swine flu pandemic, only one — GSK’s […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

April 2019 Focus: Healthcare agency & network profiles, industry overview & awards, and more!


Ad Right Bottom